AXIM Biotechnologies Inc. (OTCMKTS: AXIM) has finalized pre-clinical drug studies on the patent waiting for compound SPX-1009, showing malignant metastatic melanoma cells suppression. Dr. Douglas Lake’s lab at Arizona State University completed the independent research.
AXIM finalizes SPX-1009 studies
John W. Huemoeller II, AXIM Biotechnologies CEO, said, “We are extremely excited with the results of the in vitro testing. This potential therapeutic treatment could someday help control melanoma growth and metastasis with our compound SPX-1009 in a topical treatment.”
The study screened SPX-1009 in a cell-free enzymatic assay for the ability to suppress Quiescin Sulfhydryl oxidase I (QSOXI). QSOXI is a tumor-derived enzyme vital in cancer growth, metastasis, and invasion, which was tested for the ability to suppress invasion and growth of established A375 melanoma cell line and the low-passage patient der4eived melanoma. The study employed 3D tumor spheroid assays and 2D invasion assays to ascertain the compounds’ impact on tumor suppression.
The company’s next step is initiating animal studies to show SPX-1009’s ability to suppress metastasis and tumor growth in a murine melanoma model. In addition, the IP related to the SPX-1009 tech is subject to various patent-pending applications.
AXIM files for emergency approval for ImmunoPass
AXIM Biotechnologies recently announced that Empowered Diagnostics, its manufacturing partner, had filed an emergency approval for ImmunoPass. ImmunoPass is the company’s rapid test that measures COVID-19 neutralizing antibody levels to establish the presence of neutralizing antibodies in whole blood.
Huemoeller II said, “The COVID-19 pandemic itself is evidence that the world is interconnected. Because of that, it’s crucial that countries work together to resolve this global issue and have a consistent level of care in order to achieve relative normalcy as quickly as possible. In addition, ImmunoPass is incredibly easy to use and delivers accurate results in a matter of minutes, making it an ideal device for global use.”
CytoDyn Inc (OTCMKTS: CYDY) Announces Study to Investigate Leronlimab for Triple-negative Breast Cancer Treatment
Post Views: 18 CytoDyn Inc (OTCMKTS: CYDY) has announced that there will be a study on the drug leronlimab and...
Curaleaf Holdings Inc (OTCMKTS: CURLF) Completes Acquisition of Los Sueños Farms
Post Views: 38 Curaleaf Holdings Inc (OTCMKTS: CURLF) has completed the acquisition of the most enormous outdoor grow in Colorado,...
BAE SYSTEMS ADR (OTCMKTS: BAESY) and Keep Scotland Beautiful Launch Cleaning Hub in Govan
Post Views: 14 BAE SYSTEMS ADR (OTCMKTS: BAESY), a designer, developer and manufacturer of aerospace systems used in space, land,...
Charlotte’s Web Holdings Inc (OTCMKTS: CWBHF) Announces it Will Expand Distribution Following Passing of Assembly Bill 45
Post Views: 10 Charlotte’s Web Holdings Inc (OTCMKTS: CWBHF) has announced that it will expand product distribution in California following...
BAE Systems Inc. (OTCMKTS: BAESY) Granted five-year $68.5 Million Air Traffic Control Contract
Post Views: 12 BAE Systems Inc. (OTCMKTS: BAESY) has been picked for a 5-year $68.5M indefinite-quantity, indefinite-delivery contract enabling it...
CytoDyn Inc (OTCMKTS: CYDY) Announces Appointments of New Chief Operating Officer and Senior Executive Vice President
Post Views: 30 CytoDyn Inc (OTCMKTS: CYDY) has announced that it has appointed Nitya Ray, Ph.D., to act as its...